EMA committee recommends approvals for Lilly's weight loss drug, Mirati's KRAS inhibitor and more
The European Medicines Agency’s human medicines committee (CHMP) this week gave a thumbs-up to nine label expansions and eight new drugs, including Eli Lilly’s tirzepatide in weight management and Mirati’s Krazati in non-small cell lung cancer patients.
The positive recommendation for tirzepatide came down Thursday, a day after the fast-selling GIP/GLP-1 receptor agonist was approved in the US for the same indication. It’s known as Mounjaro in type 2 diabetes, but it will be marketed in the US for weight management as Zepbound.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
